Risk Factors Update Summary

• Expanded regulatory risks include potential penalties, fines, and injunctions for non-compliance with FDA regulations.
• The company has terminated investments in biotherapeutics and other programs, renegotiating agreements. This may lead to uncertain future revenue streams.
• Increased focus on data protection laws and regulations, including GDPR, may result in fines up to €20 million or 4% of global turnover.
• The company is refining its strategic focus, potentially missing more profitable opportunities. This could impact revenue.
• Changes in UK and EU data protection laws could impact business operations and data transfer mechanisms.
• The company faces competition from established players like DSM, Novozymes, and others, impacting market share.
• Reputational risks due to non-compliance with ESG practices may lead to customer scrutiny and potential loss of business.
• The company is working to qualify new contract manufacturers for enzyme production, including CDX-616.
• Potential reputational damage from perceived inadequate action in ESG areas could negatively impact the company's image.
• The company uses hazardous materials, facing potential liability for injury or contamination resulting from their use.
• Uncertainty in the relationship between UK and EU data protection laws may affect business operations and data transfer mechanisms.
• The company's ability to use net operating loss carryforwards may be limited, impacting future taxable income.
• Subjective assessment of ESG criteria by stakeholders could lead to misrepresentation of the company's sustainability policies.
• The company's ongoing efforts to deploy technology in life science tools markets may fail, affecting business prospects.